216 related articles for article (PubMed ID: 23603862)
21. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide.
Godelaine D; Carrasco J; Lucas S; Karanikas V; Schuler-Thurner B; Coulie PG; Schuler G; Boon T; Van Pel A
J Immunol; 2003 Nov; 171(9):4893-7. PubMed ID: 14568970
[TBL] [Abstract][Full Text] [Related]
22. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
[TBL] [Abstract][Full Text] [Related]
23. A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination.
Speiser DE; Baumgaertner P; Barbey C; Rubio-Godoy V; Moulin A; Corthesy P; Devevre E; Dietrich PY; Rimoldi D; LiƩnard D; Cerottini JC; Romero P; Rufer N
J Immunol; 2006 Jul; 177(2):1338-48. PubMed ID: 16818795
[TBL] [Abstract][Full Text] [Related]
24. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732
[TBL] [Abstract][Full Text] [Related]
25. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule.
Slingluff CL; Petroni GR; Yamshchikov GV; Hibbitts S; Grosh WW; Chianese-Bullock KA; Bissonette EA; Barnd DL; Deacon DH; Patterson JW; Parekh J; Neese PY; Woodson EM; Wiernasz CJ; Merrill P
J Clin Oncol; 2004 Nov; 22(22):4474-85. PubMed ID: 15542798
[TBL] [Abstract][Full Text] [Related]
26. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
Schultz ES; Schuler-Thurner B; Stroobant V; Jenne L; Berger TG; Thielemanns K; van der Bruggen P; Schuler G
J Immunol; 2004 Jan; 172(2):1304-10. PubMed ID: 14707109
[TBL] [Abstract][Full Text] [Related]
27. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site.
Appay V; Jandus C; Voelter V; Reynard S; Coupland SE; Rimoldi D; Lienard D; Guillaume P; Krieg AM; Cerottini JC; Romero P; Leyvraz S; Rufer N; Speiser DE
J Immunol; 2006 Aug; 177(3):1670-8. PubMed ID: 16849476
[TBL] [Abstract][Full Text] [Related]
28. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
[TBL] [Abstract][Full Text] [Related]
29. Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide.
Meijer SL; Dols A; Jensen SM; Hu HM; Miller W; Walker E; Romero P; Fox BA; Urba WJ
J Immunother; 2007; 30(5):533-43. PubMed ID: 17589294
[TBL] [Abstract][Full Text] [Related]
30. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.
Atanackovic D; Altorki NK; Stockert E; Williamson B; Jungbluth AA; Ritter E; Santiago D; Ferrara CA; Matsuo M; Selvakumar A; Dupont B; Chen YT; Hoffman EW; Ritter G; Old LJ; Gnjatic S
J Immunol; 2004 Mar; 172(5):3289-96. PubMed ID: 14978137
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.
Meneveau MO; Petroni GR; Salerno EP; Lynch KT; Smolkin M; Woodson E; Chianese-Bullock KA; Olson WC; Deacon D; Patterson JW; Grosh WW; Slingluff CL
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035112
[TBL] [Abstract][Full Text] [Related]
32. Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment.
Pollack KE; Meneveau MO; Melssen MM; Lynch KT; Koeppel AF; Young SJ; Turner S; Kumar P; Sol-Church K; Mauldin IS; Slingluff CL
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32350119
[TBL] [Abstract][Full Text] [Related]
33. High Peptide Dose Vaccination Promotes the Early Selection of Tumor Antigen-Specific CD8 T-Cells of Enhanced Functional Competence.
Carretero-Iglesia L; Couturaud B; Baumgaertner P; Schmidt J; Maby-El Hajjami H; Speiser DE; Hebeisen M; Rufer N
Front Immunol; 2019; 10():3016. PubMed ID: 31969886
[TBL] [Abstract][Full Text] [Related]
34. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
35. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
[TBL] [Abstract][Full Text] [Related]
36. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.
Powell DJ; Dudley ME; Hogan KA; Wunderlich JR; Rosenberg SA
J Immunol; 2006 Nov; 177(9):6527-39. PubMed ID: 17056585
[TBL] [Abstract][Full Text] [Related]
37. Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide.
Appay V; Speiser DE; Rufer N; Reynard S; Barbey C; Cerottini JC; Leyvraz S; Pinilla C; Romero P
Eur J Immunol; 2006 Jul; 36(7):1805-14. PubMed ID: 16761313
[TBL] [Abstract][Full Text] [Related]
38. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination.
Tsuji T; Altorki NK; Ritter G; Old LJ; Gnjatic S
J Immunol; 2009 Oct; 183(7):4800-8. PubMed ID: 19734225
[TBL] [Abstract][Full Text] [Related]
39. A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccination.
Rogel A; Vignard V; Bobinet M; Labarriere N; Lang F
Cancer Immunol Immunother; 2011 Mar; 60(3):327-37. PubMed ID: 21080167
[TBL] [Abstract][Full Text] [Related]
40. Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma.
Reynolds SR; Zeleniuch-Jacquotte A; Shapiro RL; Roses DF; Harris MN; Johnston D; Bystryn JC
Clin Cancer Res; 2003 Feb; 9(2):657-62. PubMed ID: 12576432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]